Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inotuzumab ozogamicin - Pfizer

Drug Profile

Inotuzumab ozogamicin - Pfizer

Alternative Names: BESPONSA; CMC-544; InO - Pfizer; PF-05208773; PF-5208773; WAY-207294

Latest Information Update: 27 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celltech Group; Wyeth
  • Developer Pfizer
  • Class Antineoplastics; Cytostatic antibiotics; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action DNA damage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Chronic myeloid leukaemia
  • Phase I Acute biphenotypic leukaemia; Burkitt's lymphoma
  • Discontinued Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 26 Mar 2024 Launched for Precursor cell lymphoblastic leukaemia-lymphoma (In children, Second-line therapy or greater) in Japan (IV)
  • 26 Mar 2024 Registered for Precursor cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater, In children) in Japan (IV)
  • 06 Mar 2024 Launched for Precursor B-cell lymphoblastic leukaemia-lymphoma (In adolescents, In children, In infants, Second-line therapy or greater) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top